105 related articles for article (PubMed ID: 1684096)
1. Biological correlation between HER-2/neu and proliferative activity in human breast cancer.
Tommasi S; Paradiso A; Mangia A; Barletta A; Simone G; Slamon DJ; De Lena M
Anticancer Res; 1991; 11(4):1395-400. PubMed ID: 1684096
[TBL] [Abstract][Full Text] [Related]
2. Comparative long-term prognostic value of quantitative HER-2/neu protein expression, DNA ploidy, and morphometric and clinical features in paraffin-embedded invasive breast cancer.
Baak JP; Chin D; van Diest PJ; Ortiz R; Matze-Cok P; Bacus SS
Lab Invest; 1991 Feb; 64(2):215-23. PubMed ID: 1671789
[TBL] [Abstract][Full Text] [Related]
3. HER-2/neu amplification predicts poor survival in node-positive breast cancer.
Borg A; Tandon AK; Sigurdsson H; Clark GM; Fernö M; Fuqua SA; Killander D; McGuire WL
Cancer Res; 1990 Jul; 50(14):4332-7. PubMed ID: 1973070
[TBL] [Abstract][Full Text] [Related]
4. Her-2/neu oncogene expression in Puerto Rican females with breast cancer.
Peredo R; Sastre G; Serrano J; Hunter Mellado R
Cell Mol Biol (Noisy-le-grand); 2001 Sep; 47(6):1025-32. PubMed ID: 11785652
[TBL] [Abstract][Full Text] [Related]
5. DNA ploidy, proliferation, and neu-oncogene protein overexpression in breast carcinoma.
Lee AK; Wiley B; Loda M; Bosari S; Dugan JM; Hamilton W; Heatley GJ; Cook L; Silverman ML
Mod Pathol; 1992 Jan; 5(1):61-7. PubMed ID: 1347424
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous analysis of c-erbB-2 expression and DNA content in breast cancer using flow cytometry.
Stål O; Sullivan S; Sun XF; Wingren S; Nordenskjöld B
Cytometry; 1994 Jun; 16(2):160-8. PubMed ID: 7924685
[TBL] [Abstract][Full Text] [Related]
7. Mutant p53 expression and DNA analysis in human breast cancer comparison with conventional clinicopathological parameters.
Rosanelli GP; Steindorfer P; Wirnsberger GH; Klimpfinger M; Ratschek M; Puerstner P; Auner H; Berhold A
Anticancer Res; 1995; 15(2):581-6. PubMed ID: 7763041
[TBL] [Abstract][Full Text] [Related]
8. Detection of c-erbB-2 oncoprotein expression in breast tissue by multiparameter flow cytometry.
Li BD; Bauer KD; Carney WP; Duda RB
J Surg Res; 1993 Mar; 54(3):179-88. PubMed ID: 7682635
[TBL] [Abstract][Full Text] [Related]
9. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
10. Intracellular coexpression of epidermal growth factor receptor, Her-2/neu, and p21ras in human breast cancers: evidence for the existence of distinctive patterns of genetic evolution that are common to tumors from different patients.
Shackney SE; Pollice AA; Smith CA; Janocko LE; Sweeney L; Brown KA; Singh SG; Gu L; Yakulis R; Lucke JF
Clin Cancer Res; 1998 Apr; 4(4):913-28. PubMed ID: 9563885
[TBL] [Abstract][Full Text] [Related]
11. Correlations among p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas.
Smith CA; Pollice AA; Gu LP; Brown KA; Singh SG; Janocko LE; Johnson R; Julian T; Hyams D; Wolmark N; Sweeney L; Silverman JF; Shackney SE
Clin Cancer Res; 2000 Jan; 6(1):112-26. PubMed ID: 10656439
[TBL] [Abstract][Full Text] [Related]
12. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.
Prati R; Apple SK; He J; Gornbein JA; Chang HR
Breast J; 2005; 11(6):433-9. PubMed ID: 16297088
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis.
Guérin M; Barrois M; Terrier MJ; Spielmann M; Riou G
Oncogene Res; 1988; 3(1):21-31. PubMed ID: 2905033
[TBL] [Abstract][Full Text] [Related]
14. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A
Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951
[TBL] [Abstract][Full Text] [Related]
15. ras, c-myc and c-erbB-2 oncoproteins in human breast cancer.
Spandidos DA; Yiagnisis M; Papadimitriou K; Field JK
Anticancer Res; 1989; 9(5):1385-93. PubMed ID: 2574023
[TBL] [Abstract][Full Text] [Related]
16. HER-2/neu oncogene expression and DNA ploidy analysis in breast cancer.
Bacus SS; Bacus JW; Slamon DJ; Press MF
Arch Pathol Lab Med; 1990 Feb; 114(2):164-9. PubMed ID: 1967930
[TBL] [Abstract][Full Text] [Related]
17. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.
Ariga R; Zarif A; Korasick J; Reddy V; Siziopikou K; Gattuso P
Breast J; 2005; 11(4):278-80. PubMed ID: 15982396
[TBL] [Abstract][Full Text] [Related]
18. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R
Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689
[TBL] [Abstract][Full Text] [Related]
19. [Immunohistochemical research on breast cancer cell proliferation and hormonal receptor status with special emphasis on HER-2/neu expression].
Ohlinger R; Steffen SM; Oellig F; Köhler G; Schwesinger G; Lorenz G
Zentralbl Gynakol; 2002 Oct; 124(10):473-7. PubMed ID: 12712389
[TBL] [Abstract][Full Text] [Related]
20. Tumor-proliferative activity, progesterone receptor status, estrogen receptor level, and clinical outcome of estrogen receptor-positive advanced breast cancer.
Paradiso A; Tommasi S; Mangia A; Lorusso V; Simone G; De Lena M
Cancer Res; 1990 May; 50(10):2958-62. PubMed ID: 2334898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
